|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
EP3252079B8
(en)
|
2006-04-07 |
2020-09-09 |
Aerpio Therapeutics LLC |
Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
|
|
US8475785B2
(en)
|
2008-03-03 |
2013-07-02 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
EP2504028A4
(en)
*
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
US9402916B2
(en)
|
2011-03-17 |
2016-08-02 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
US9822179B2
(en)
*
|
2011-04-01 |
2017-11-21 |
Universitat Stuttgart |
Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor
|
|
RU2018119112A
(ru)
*
|
2011-05-27 |
2018-11-07 |
Эббви Байотекнолоджи Лтд. |
Композиции и способы на основе dac hyp
|
|
CN104039351A
(zh)
|
2011-10-13 |
2014-09-10 |
阿尔皮奥治疗学股份有限公司 |
用于治疗血管渗漏综合征和癌症的方法
|
|
ES2918580T3
(es)
|
2011-10-17 |
2022-07-19 |
Io Biotech Aps |
Inmunoterapia basada en PD-L1
|
|
JP6602012B2
(ja)
*
|
2012-02-10 |
2019-11-06 |
シアトル ジェネティクス インコーポレーテッド |
Ｃｄ３０＋癌の検出と治療
|
|
MX2014013041A
(es)
|
2012-04-27 |
2015-03-19 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se ligan al receptor del factor de crecimiento epidermico y metodos de uso de los mismos.
|
|
MY174248A
(en)
|
2012-04-30 |
2020-04-01 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
WO2014121099A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Agonist fusion protein for cd40 ox40 and uses thereof
|
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
|
PT2953634T
(pt)
|
2013-02-07 |
2021-09-02 |
Massachusetts Gen Hospital |
Métodos de expansão ou depleção das células t reguladoras
|
|
CN105121474B9
(zh)
|
2013-03-12 |
2020-06-19 |
比奥孔有限公司 |
融合免疫调节蛋白及其制备方法
|
|
CN105209069B
(zh)
|
2013-03-13 |
2019-08-23 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
|
WO2014168715A1
(en)
*
|
2013-04-08 |
2014-10-16 |
R-Pharm Overseas, Inc. |
B7 ligands/cd20 inhibitor composition and use thereof
|
|
AU2014254019B2
(en)
|
2013-04-18 |
2018-09-27 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
DK3406633T3
(da)
|
2013-07-25 |
2022-03-28 |
Cytomx Therapeutics Inc |
Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
|
|
CN105658672A
(zh)
*
|
2013-08-22 |
2016-06-08 |
阿塞勒隆制药公司 |
TGF-β受体II型变体及其用途
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
MX2016005915A
(es)
*
|
2013-11-11 |
2016-12-16 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
JP2017507931A
(ja)
*
|
2014-02-05 |
2017-03-23 |
シーダーズ−サイナイ メディカル センター |
がん及び感染症の治療方法並びに治療用組成物
|
|
MX381141B
(es)
|
2014-02-10 |
2025-03-12 |
Merck Patent Gmbh |
INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
|
|
US20170165364A1
(en)
*
|
2014-02-21 |
2017-06-15 |
Idac Theranostics, Inc. |
Therapeutic agent for solid cancer
|
|
MX2016010998A
(es)
|
2014-02-27 |
2017-03-31 |
Lycera Corp |
Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
US20150307620A1
(en)
*
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞（上海）生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
|
WO2015178746A1
(ko)
*
|
2014-05-23 |
2015-11-26 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
AU2015266958A1
(en)
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
JP6449338B2
(ja)
|
2014-06-06 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
EP3156072B1
(en)
*
|
2014-06-11 |
2020-08-19 |
IDAC Theranostics, Inc. |
Method for reducing side effects of immune checkpoint control agent
|
|
MX378790B
(es)
*
|
2014-07-21 |
2025-03-10 |
Delinia Inc |
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
SG11201700629TA
(en)
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
JP7072384B2
(ja)
|
2014-09-15 |
2022-05-20 |
ジェネンテック， インコーポレイテッド |
抗体製剤
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
DK3489256T3
(da)
|
2014-11-14 |
2021-05-25 |
Hoffmann La Roche |
Antigenbindende molekyler omfattende en TNF-familieligandtrimer
|
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
KR20170137079A
(ko)
*
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
|
EP3973980A1
(en)
|
2015-03-31 |
2022-03-30 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a trimeric tnf family ligand
|
|
WO2016164799A1
(en)
|
2015-04-10 |
2016-10-13 |
The Regents Of The University Of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
EP4140492A1
(en)
|
2015-04-21 |
2023-03-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
AU2016258977C1
(en)
*
|
2015-05-04 |
2022-07-14 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
AU2016263198C1
(en)
|
2015-05-15 |
2023-10-05 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
JP6812364B2
(ja)
|
2015-06-03 |
2021-01-13 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌診断用抗ｇｉｔｒ抗体
|
|
HK1253734A1
(zh)
|
2015-06-11 |
2019-06-28 |
The Regents Of The University Of Michigan |
用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
CN116059219A
(zh)
|
2015-07-16 |
2023-05-05 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
WO2017019729A1
(en)
|
2015-07-27 |
2017-02-02 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
|
EP3340999A4
(en)
|
2015-08-28 |
2019-06-12 |
The General Hospital Corporation |
AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
AU2016322934A1
(en)
*
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
|
US10183060B2
(en)
*
|
2015-10-01 |
2019-01-22 |
Heat Biologics, Inc. |
Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
US20170107510A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Batu Biologics, Inc. |
Dna nanoparticle based checkpoint inhibitors
|
|
CN108472365A
(zh)
|
2015-10-30 |
2018-08-31 |
艾丽塔生物治疗剂公司 |
用于肿瘤转导的组合物和方法
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
US11219645B2
(en)
|
2015-11-18 |
2022-01-11 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
|
CN108738324B
(zh)
|
2015-11-19 |
2022-06-21 |
百时美施贵宝公司 |
抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
WO2017106129A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Anti-lag3 antibodies and antigen-binding fragments
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
ES2908848T3
(es)
*
|
2016-01-25 |
2022-05-04 |
Sanofi Sa |
Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
EP3455262A4
(en)
|
2016-05-13 |
2020-04-08 |
The General Hospital Corporation |
ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
|
|
US11352413B2
(en)
|
2016-05-17 |
2022-06-07 |
Albert Einstein College Of Medicine |
Engineered PD-1 variants
|
|
JP7632835B2
(ja)
*
|
2016-05-20 |
2025-02-19 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
加齢関連疾患及び症状の遺伝子治療法
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
WO2017220602A1
(en)
|
2016-06-21 |
2017-12-28 |
Herlev Hospital |
Pdl1 peptides for use in cancer vaccines
|
|
KR102726248B1
(ko)
|
2016-07-07 |
2024-11-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
JP7421338B2
(ja)
|
2016-09-27 |
2024-01-24 |
エピセントアールエックス，インコーポレイテッド |
免疫調節融合タンパク質
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
US20200038509A1
(en)
*
|
2016-10-14 |
2020-02-06 |
Baylor College Of Medicine |
Radiofrequency field hyperthermia and solid tumor immunomodulation
|
|
US20190256573A1
(en)
*
|
2016-10-14 |
2019-08-22 |
Emory University |
Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
|
|
WO2018089420A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
|
|
CN110234319B
(zh)
|
2016-11-23 |
2022-09-27 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
JP7227131B2
(ja)
|
2016-12-03 |
2023-02-21 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃａｒ－ｔ細胞の投薬を決定するための方法
|
|
BR112019011207A2
(pt)
|
2016-12-05 |
2019-10-08 |
Juno Therapeutics Inc |
produção de células modificadas para terapia celular adotiva
|
|
HRP20230937T1
(hr)
*
|
2017-01-05 |
2023-11-24 |
Kahr Medical Ltd. |
Pd1-41bbl fuzijski protein i metode korištenja istog
|
|
WO2018127916A1
(en)
*
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
PT3565828T
(pt)
*
|
2017-01-05 |
2022-02-08 |
Kahr Medical Ltd |
Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
|
|
WO2018127918A1
(en)
*
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A sirp alpha-cd70 fusion protein and methods of use thereof
|
|
JP2020514290A
(ja)
*
|
2017-01-07 |
2020-05-21 |
メルク パテント ゲーエムベーハー |
標的ｔｇｆ−β阻害のための投薬計画及び投薬形態
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
AU2018214979A1
(en)
*
|
2017-02-01 |
2019-08-15 |
Acceleron Pharma Inc. |
TGFβ and actrii antagonists for use in increasing immune activity
|
|
CA3052523A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
|
BR112019017713A2
(pt)
|
2017-02-27 |
2020-04-07 |
Shattuck Labs Inc |
proteínas quiméricas à base de csf1r
|
|
IL268198B2
(en)
*
|
2017-02-27 |
2024-10-01 |
Shattuck Labs Inc |
Tigit- and light-based chimeric proteins
|
|
CN118184797A
(zh)
|
2017-02-27 |
2024-06-14 |
沙塔克实验室有限公司 |
基于vsig8的嵌合蛋白
|
|
JP7231553B2
(ja)
|
2017-03-02 |
2023-03-01 |
ナショナル リサーチ カウンシル オブ カナダ |
Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3600378A4
(en)
*
|
2017-03-24 |
2020-12-23 |
Orpheus Bioscience Inc. |
PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
|
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
EP3615564A1
(en)
*
|
2017-04-24 |
2020-03-04 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
CN110785431B
(zh)
*
|
2017-05-04 |
2024-05-07 |
阿塞勒隆制药公司 |
TGF-β受体II型融合蛋白及其用途
|
|
IL270415B2
(en)
|
2017-05-12 |
2024-08-01 |
Crispr Therapeutics Ag |
Materials and methods for cell engineering and their uses in immuno-oncology
|
|
UA128306C2
(uk)
*
|
2017-05-12 |
2024-06-05 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
|
WO2018213747A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Merrimack Pharmaceuticals, Inc. |
4-1bb agonist and cd40 agonist bispecific molecules
|
|
JP7173993B2
(ja)
|
2017-05-19 |
2022-11-17 |
ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド |
細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
CN107857819A
(zh)
*
|
2017-07-03 |
2018-03-30 |
江苏西迪尔生物技术有限公司 |
多功能融合蛋白及其应用
|
|
ES2910969T3
(es)
|
2017-08-03 |
2022-05-17 |
Amgen Inc |
Muteínas de interleucina-21 y métodos de tratamiento
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
CN107602705B
(zh)
*
|
2017-09-13 |
2018-08-31 |
北京鼎成肽源生物技术有限公司 |
一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用
|
|
AU2018338612A1
(en)
|
2017-09-27 |
2020-05-07 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
CN111164099A
(zh)
*
|
2017-09-29 |
2020-05-15 |
河谷细胞有限公司 |
抗原蛋白及其方法
|
|
JP7749319B2
(ja)
|
2017-10-10 |
2025-10-06 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
|
|
AU2018347607B2
(en)
|
2017-10-14 |
2025-08-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
KR20250010043A
(ko)
|
2017-10-18 |
2025-01-20 |
프레시전 인코포레이티드 |
스페이서를 포함하는 폴리펩타이드 조성물
|
|
EP3706786A4
(en)
*
|
2017-11-09 |
2021-09-01 |
Medimmune, LLC |
BIS SPECIFIC FUSION POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
|
WO2019113123A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Precithera, Inc. |
TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
|
|
US20200377571A1
(en)
*
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗ｐｄ-１抗體及治療方法
|
|
CN110151309B
(zh)
*
|
2018-02-14 |
2022-02-15 |
上海美杰医疗科技有限公司 |
多模态消融治疗术前规划方法及其设备
|
|
CN112119157B
(zh)
|
2018-03-06 |
2025-01-14 |
宾夕法尼亚大学董事会 |
前列腺特异性膜抗原car及其使用方法
|
|
BR112020017382A2
(pt)
|
2018-03-09 |
2021-01-26 |
Agenus Inc. |
anticorpos anti-cd73 e métodos de uso dos mesmos
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US11168138B2
(en)
*
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
CA3099325A1
(en)
*
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
Novel binders of tgf.beta.-superfamily ligands and uses thereof
|
|
AU2019262139A1
(en)
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
|
BR112020022145A2
(pt)
*
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
|
WO2019215500A1
(en)
|
2018-05-11 |
2019-11-14 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
JP2021526835A
(ja)
*
|
2018-06-15 |
2021-10-11 |
アクセルロン ファーマ インコーポレイテッド |
二機能性および三機能性融合タンパク質およびその使用
|
|
CA3102641A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
EP3813864A4
(en)
*
|
2018-06-29 |
2022-07-20 |
Gensun Biopharma Inc. |
Antitumor antagonists
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2019301070B2
(en)
|
2018-07-09 |
2025-09-11 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
KR20210044220A
(ko)
|
2018-07-11 |
2021-04-22 |
카 메디컬 리미티드 |
SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
|
|
SG11202013170RA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
Pd1-4-1bbl variant fusion protein and methods of use thereof
|
|
WO2020033646A1
(en)
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
|
CN120058958A
(zh)
|
2018-09-24 |
2025-05-30 |
视点制药公司 |
靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
|
|
WO2020069372A1
(en)
|
2018-09-27 |
2020-04-02 |
Elstar Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
US20220034880A1
(en)
*
|
2018-10-01 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
|
|
CN118356479A
(zh)
|
2018-10-17 |
2024-07-19 |
百欧林纳克斯有限公司 |
转移性胰脏腺癌的治疗
|
|
JP2022512688A
(ja)
*
|
2018-10-24 |
2022-02-07 |
シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド |
Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
|
|
JP2022505925A
(ja)
|
2018-11-01 |
2022-01-14 |
メルク パテント ゲーエムベーハー |
抗ｔｉｍ－３抗体
|
|
AU2019372436A1
(en)
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
KR102881644B1
(ko)
|
2018-11-09 |
2025-11-06 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도
|
|
CN113302205B
(zh)
|
2018-11-15 |
2024-12-06 |
综合医院公司 |
激动性肿瘤坏死因子受体超家族多肽
|
|
EP3893888A4
(en)
*
|
2018-12-10 |
2022-08-31 |
Bioxcel Therapeutics, Inc. |
COMBINATION THERAPIES FOR TREATING DISEASES USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST
|
|
KR20210141447A
(ko)
|
2018-12-26 |
2021-11-23 |
실리오 디벨럽먼트, 인크. |
항-ctla4 항체 및 이의 사용 방법
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
|
CA3130794A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
US12109235B2
(en)
*
|
2019-06-21 |
2024-10-08 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
|
JP7616671B2
(ja)
|
2019-06-24 |
2025-01-17 |
ウニヴェルズィテート シュトゥットガルト |
改善された安定性を有するｔｎｆｒ２アゴニスト
|
|
WO2020263312A1
(en)
*
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
EP3999527A4
(en)
*
|
2019-07-18 |
2024-04-17 |
Memorial Sloan Kettering Cancer Center |
METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
|
|
JP7771749B2
(ja)
*
|
2019-08-08 |
2025-11-18 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
WO2021041886A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified n-810 and methods therefor
|
|
CN114072428B
(zh)
*
|
2019-08-30 |
2024-02-13 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
KR20210033436A
(ko)
*
|
2019-09-18 |
2021-03-26 |
주식회사 에스엘바이젠 |
신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
|
|
CN110734498A
(zh)
*
|
2019-10-15 |
2020-01-31 |
上海科棋药业科技有限公司 |
一种用于解除免疫抑制的融合蛋白及其应用
|
|
EP4048704A4
(en)
*
|
2019-10-21 |
2023-11-22 |
Nanjing Leads Biolabs Co., Ltd. |
RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
|
|
TW202130655A
(zh)
|
2019-10-23 |
2021-08-16 |
美商庫爾生物製藥有限公司 |
ＴＧＦ—β多肽
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
TWI772984B
(zh)
|
2019-11-27 |
2022-08-01 |
大陸商上海岸邁生物科技有限公司 |
TGFβ/PD-L1雙特異性結合蛋白
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
EP4186517A4
(en)
*
|
2020-01-23 |
2024-05-29 |
Genexine, Inc. |
FUSION PROTEIN COMPRISING PD-L1 PROTEIN AND USE THEREOF
|
|
US11912751B2
(en)
*
|
2020-01-31 |
2024-02-27 |
Globetek Science Foundation |
Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains
|
|
CN115427438A
(zh)
|
2020-02-27 |
2022-12-02 |
迈斯特治疗公司 |
肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
|
|
WO2021209049A1
(zh)
*
|
2020-04-16 |
2021-10-21 |
南通壹宸生物医药科技有限公司 |
一种pd-1突变体多肽及其制备和用途
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2021264846B2
(en)
*
|
2020-04-28 |
2025-03-06 |
Sinocelltech Ltd. |
TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein
|
|
CN111690070A
(zh)
*
|
2020-05-13 |
2020-09-22 |
深圳市众循精准医学研究院 |
一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
IL299764A
(en)
*
|
2020-07-10 |
2023-03-01 |
Precigen Inc |
Fusion constructs and methods for using them
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
EP4232063A4
(en)
*
|
2020-10-23 |
2025-01-01 |
HAN, Hq |
BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
|
|
CA3197104A1
(en)
*
|
2020-11-11 |
2022-05-19 |
Hq Han |
Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
US20240084018A1
(en)
*
|
2020-12-15 |
2024-03-14 |
Bicara Therapeutics Inc. |
Pharmaceutical formulations for fusion proteins
|
|
CA3202374A1
(en)
*
|
2020-12-15 |
2022-06-23 |
Bicara Therapeutics Inc. |
Combination therapy for the treatment of cancer
|
|
US11672844B2
(en)
*
|
2021-02-17 |
2023-06-13 |
Cura Therapeutics, Inc. |
Method of treating or ameliorating a pathogenic infection by administering an interleukin-2/TGF-β receptor fusion polypeptide
|
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
|
|
KR20240017937A
(ko)
*
|
2021-06-07 |
2024-02-08 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
치료제의 표적화된 전달을 위한 조성물 및 방법
|
|
AU2022291365B2
(en)
|
2021-06-08 |
2026-03-12 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
EP4373499A4
(en)
*
|
2021-07-21 |
2025-04-23 |
Mayo Foundation for Medical Education and Research |
Promoting immune surveillance against cancer cells
|
|
CA3230292A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
|
|
CN118302439A
(zh)
*
|
2021-09-24 |
2024-07-05 |
生物系统株式会社 |
包含pd-1和il-21的融合蛋白二聚体及其用途
|
|
IL312049A
(en)
|
2021-10-11 |
2024-06-01 |
Y Trap Inc |
Compositions and methods that inhibit il-23 signaling
|
|
WO2023086812A1
(en)
*
|
2021-11-11 |
2023-05-19 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
CA3239434A1
(en)
*
|
2022-01-18 |
2023-07-27 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
EP4514834A1
(en)
*
|
2022-04-28 |
2025-03-05 |
Immatics US, Inc. |
Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
|
|
WO2024006746A1
(en)
*
|
2022-06-29 |
2024-01-04 |
Cdres Pharma Llc |
Immunologically active polypeptide
|
|
WO2024215772A2
(en)
*
|
2023-04-11 |
2024-10-17 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
CN116514913B
(zh)
*
|
2023-06-07 |
2025-03-21 |
澳门大学 |
具有抗肿瘤活性的tnfr2靶向肽及其应用
|
|
TW202517668A
(zh)
*
|
2023-06-26 |
2025-05-01 |
寶泰生醫股份有限公司 |
治療癌症的組合物與方法
|